Recovery after unilateral knee replacement due to severe osteoarthritis and progression in the contralateral knee: a randomised clinical trial comparing daily 2000 IU versus 800 IU vitamin D.

OBJECTIVE: To test whether daily high-dose vitamin D improves recovery after unilateral total knee replacement. METHODS: Data come from a 24-month randomised, double-blind clinical trial. Adults aged 60 and older undergoing unilateral joint replacement due to severe knee osteoarthritis were 6-8 weeks after surgery randomly assigned to receive daily high-dose (2000 IU) or standard-dose (800 IU) vitamin D3. The primary endpoints were symptoms (Western Ontario and McMaster Universities Arthritis Index pain and function scores) assessed at baseline, 6, 12, 18 and 24 months in both knees, and the rate of falls over 24 months. The secondary outcomes were sit-to-stand performance, gait speed, physical activity and radiographic progression in the contralateral knee. RESULTS: We recruited 273 participants, 137 were randomised to receive 2000 IU and 136 were randomised to receive 800 IU vitamin D per day. 2000 IU vitamin D increased 25-hydroxyvitamin D levels to 45.6 ng/mL and 800 IU vitamin D to 37.1 ng/mL at month 24 (p<0.0001). While symptoms improved significantly in the operated knee and remained stable in the contralateral knee over time, none of the primary or secondary endpoints differed by treatment group over time. The rate of falls over 24 months was 1.05 with 2000 IU and 1.07 with 800 IU (p=0.84). 30.5% of participants in the 2000 IU and 31.3% of participants in the 800 IU group had radiographic progression in the contralateral knee over 24 months (p=0.88). CONCLUSIONS: Our findings suggest that a 24-month treatment with daily 2000 IU vitamin D did not show greater benefits or harm than a daily standard dose of 800 IU among older adults undergoing unilateral total knee replacement.

Calcium revisited, part III: effect of dietary calcium on BMD and fracture risk.

Food can be an excellent source of calcium. Dietary calcium is in general as well absorbed as calcium supplements, and exerts the same effects on bone. The main sources are dairy products, but also some vegetables and fruits contain considerable amounts of calcium. Mineral water can serve as a supplement. Cross-sectional, longitudinal and some interventional trials have shown positive effects on bone metabolism, bone density and bone loss. But the effect on fracture incidence is less certain, and that of milk, the most studied dairy product, still unproven.

Calcium revisited: part II calcium supplements and their effects.

Calcium supplements were tested in pregnancy and lactation, in childhood and adolescence, in pre- and postmenopausal women and in elderly persons with various effects on bone density and fracture incidence. They must be properly chosen and adequately used. In this case, the reported minor negative side-effects do not restrict their use. All these aspects are reviewed here.

Calcium revisited: part I.

In February 2013, the US Preventive Services Task Force (see www.uspreventiveservicestaskforce.org) recommended 'against daily supplementation with 400 IU or less of vitamin D3 and 1000, mg or less of calcium for the primary prevention of fractures in non institutionalized postmenopausal women', which illustrates the divergence of opinions. This review wants to shed an objective light on the importance of calcium for bone health. It cannot compete with an exhaustive analysis of the literature by an institute. It does not mention all significant references. But it highlights some pivotal studies from the past and it refers to recent studies that opened new views or added essential data to known facts. It also reflects the personal perception of the author. The first part deals mainly with intake, absorption, needs and recommendations; the second part will discuss the effects of calcium and its supplements on bone.

[Calcium and Vitamin D in the treatment and prevention of osteoporosis: the actual dilemma]. / Kalzium und Vitamin D in Therapie und Prävention der Osteoporose - Aktuelle Widersprüche.

Calcium lowers the fracture risk when given together with vitamin D. In many patients the Calcium intake is lower than the recommended amount, because the mean value reported in several studies corresponds just to the recommended intake, which means that half of the population is below. The American Institute of Medicine (IOM) recommends 1200 mg per day. But 1000 mg should be enough in the presence of vitamin D sufficieny, particularly because 800 mg are the lowest limit for avoiding bone loss. In general, higher doses are harmless. When the Calcium intake ca not be increased by nutrition, supplements are indicated. It is not proven that they increase the cardiovascular risk, which anyway was not reported in the combination with vitamin D, neither with nutritional Calcium. Therefore, Calcium hast to be prescribed in the treatment of osteoporosis, after meal. Vitamin D too is deficient in most of the patients with osteoporosis, especially in advanced age, and should be prescribed together with Calcium, because it hardly can be delivered by food. Although there is no toxicity up to 10'000 IU par day, the IOM proposes only 600 IU per day, and by that neglects the fact that this dose hardly leads to a blood level of 25-OH vitamin D which goes along with lower fracture risk, and wich leaves a large part of the patients vitamin D deficient, unfit for optimal reaction to treatment. Swiss, German and American specialists too recommend 800 - 2000 IU per day.

Alkaline mineral water lowers bone resorption even in calcium sufficiency: alkaline mineral water and bone metabolism.

BACKGROUND: Dietary acid charge enhances bone loss. Bicarbonate or alkali diet decreases bone resorption in humans. We compared the effect of an alkaline mineral water, rich in bicarbonate, with that of an acid one, rich in calcium only, on bone markers, in young women with a normal calcium intake. METHODS: This study compared water A (per litre: 520 mg Ca, 291 mg HCO(3)(-), 1160 mg SO(4)(-), Potential Renal Acid load (PRAL) +9.2 mEq) with water B (per litre: 547 mg Ca, 2172 mg HCO(3)(-), 9 mg SO(4)(-), PRAL -11.2 mEq). 30 female dieticians aged 26.3 yrs (SD 7.3) were randomized into two groups, followed an identical weighed, balanced diet (965 mg Ca) and drank 1.5 l/d of the assigned water. Changes in blood and urine electrolytes, C-telopeptides (CTX), urinary pH and bicarbonate, and serum PTH were measured after 2 and 4 weeks. RESULTS: The two groups were not different at baseline, and showed a similar increase in urinary calcium excretion. Urinary pH and bicarbonate excretion increased with water B, but not with water A. PTH (p=0.022) and S-CTX (p=0.023) decreased with water B but not with water A. CONCLUSION: In calcium sufficiency, the acid calcium-rich water had no effect on bone resorption, while the alkaline water rich in bicarbonate led to a significant decrease of PTH and of S-CTX.

The effect of the alkali load of mineral water on bone metabolism: interventional studies.

Alkali supplements decrease bone resorption and increase bone mineral density. Alkali diets also lower bone resorption. Mineral waters alone could have such an effect. In several subsequent studies in humans, bicarbonate-rich alkali mineral waters with low potential renal acid load values were shown to decrease bone resorption markers and even parathyroid hormone levels. This effect seems to be stronger than that of acidic calcium-rich mineral waters and could also be demonstrated in calcium sufficiency.

Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials.

BACKGROUND: The role of total calcium intake in the prevention of hip fracture risk has not been well established. OBJECTIVE: The objective of the study was to assess the relation of calcium intake to the risk of hip fracture on the basis of meta-analyses of cohort studies and clinical trials. RESULTS: In women (7 prospective cohort studies, 170,991 women, 2,954 hip fractures), there was no association between total calcium intake and hip fracture risk [pooled risk ratio (RR) per 300 mg total Ca/d = 1.01; 95% CI: 0.97, 1.05]. In men (5 prospective cohort studies, 68,606 men, 214 hip fractures), the pooled RR per 300 mg total Ca/d was 0.92 (95% CI: 0.82, 1.03). On the basis of 5 clinical trials (n = 5666 women, primarily postmenopausal, plus 1074 men) with 814 nonvertebral fractures, the pooled RR for nonvertebral fractures between calcium supplementation (800-1600 mg/d) and placebo was 0.92 (95% CI: 0.81, 1.05). On the basis of 4 clinical trials with separate results for hip fracture (6,504 subjects with 139 hip fractures), the pooled RR between calcium and placebo was 1.64 (95% CI:1.02, 2.64). Sensitivity analyses including 2 additional small trials with <100 participants or per-protocol results did not substantially alter results. CONCLUSIONS: Pooled results from prospective cohort studies suggest that calcium intake is not significantly associated with hip fracture risk in women or men. Pooled results from randomized controlled trials show no reduction in hip fracture risk with calcium supplementation, and an increased risk is possible. For any nonvertebral fractures, there was a neutral effect in the randomized trials.